)
Edgewise Therapeutics (EWTX) investor relations material
Edgewise Therapeutics Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Key accomplishments and clinical progress
Achieved primary and secondary biomarker endpoints in the first controlled study for Becker muscular dystrophy, supporting a fully controlled phase 3 trial.
Phase 3 Becker trial completed enrollment in February; 18-month study with 175 patients, aiming for a readout in November–December 2026.
For HCM, demonstrated no relationship between drug concentration and ejection fraction, indicating a differentiated safety profile.
Robust efficacy data in HCM with significant improvements in KCCQ scores and NT-proBNP, showing rapid and deep effects.
Adjusted patient selection and triage in HCM trials to better match prior phase 3 studies and reduce AFib risk.
Protocol adjustments and safety measures
Implemented multi-level echo review (PI, internal expert, core lab) to ensure appropriate patient selection and minimize AFib risk.
Excluded patients with high AFib risk based on atrial size and reservoir strain, aligning with prior phase 3 criteria.
Ongoing part D of HCM study focuses on safety, with efficacy data from earlier parts and more details to be disclosed soon.
Acceptable AFib rates in upcoming updates are in the single digits, consistent with placebo rates in similar studies.
Dose finding and future plans
Enrolled additional cohorts at 25 mg to identify the minimally effective dose and inform phase 3 dosing strategy.
Dose titration in part D ranges from 25 up to 150 mg, with open-label extension to 200 mg, to guide phase 3 design.
Aim to demonstrate no need for echo monitoring, enabling broader adoption in community settings.
Phase 3 for HCM expected to start in Q4 2026, with potential for abbreviated timelines.
Next Edgewise Therapeutics earnings date
Next Edgewise Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)